\n
<\/p>\n
MH Guide\/BRCA and MH Guide\/Mendel will assist doctors and human geneticists in making decisions about gene variant pathogenicity.<\/p>\n
HEIDELBERG, Inherited genetic variants can predispose an\u00a0 individual to cancer. Hereditary Breast and Ovarian Cancer (HBOC) Syndrome, for\u00a0 example, is caused by pathogenic mutations in distinct genes such as BRCA1\/2<\/i>, MLH1<\/i>, MSH6<\/i>, PMS2<\/i>,\u00a0\u00a0 respectively. Therefore, testing BRCA1\/2<\/i>\u00a0 genes and other heritable cancer-associated genes is becoming increasingly important:\u00a0 both to evaluate the affected patient’s individual risk of developing cancer1,2<\/sup>,\u00a0 and as a predictive biomarker and companion diagnostic test for certain drugs3<\/sup>.\u00a0 Whereas MH Guide\/BRCA detects variants in HBOC-associated genes, MH Guide\/Mendel\u00a0 can analyze large gene panels as well as whole-exome or whole-genome data, so\u00a0 that many different hereditary diseases can be identified at once.<\/p>\n “With this collaboration in place, Japanese\u00a0 patients will benefit from state-of-the-art genetic identification of inherited\u00a0 diseases like Hereditary\u00a0 Breast and Ovarian Cancer and many other diseases. This will allow sooner\u00a0 diagnosis and potentially earlier therapeutic intervention”, said Christian\u00a0 Meisel, MD, PhD, Chief Medical Officer at Molecular Health.<\/p>\n Under\u00a0\u00a0 the terms of this collaboration, FALCO biosystems will perform the next-generation\u00a0\u00a0 sequencing (NGS) process and variant identification using blood samples\u00a0 provided by the patient. Molecular Health will then analyze the variant data MH 2<\/sup>\u00a0National Comprehensive Cancer \n
\nGERMANY – EQS Newswire – 2 March 2021 – Molecular Health GmbH<\/a> announced today\u00a0 that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd.<\/a> under which FALCO biosystems\u00a0 will use the products MH Guide\/BRCA and MH Guide\/Mendel to evaluate inherited\u00a0 genetic variants of BRCA1\/2<\/i> and other heritable cancer-associated genes.<\/p>\n
\nusing MH Guide\/BRCA or MH Guide\/Mendel. To accurately distinguish benign from
\npathogenic variants, MH uses an in-house proprietary database called MH Dataome, which integrates\u00a0 the Japanese reference genome ToMMo 3.5KJPNv2 (MAF \u2265 1%) for improved variant\u00a0 filtering and classification. Molecular Health gratefully acknowledges the\u00a0 contribution of Tohoku Medical Megabank.<\/p>\n
\nGuide\/BRCA and MH Guide\/Mendel are part of MH Guide, a registered in-vitro
\ndiagnostic (IVD) medical device in Europe.<\/p>\n
\n
\nNetwork. NCCN Guidelines: Genetic\/Familial High-Risk
\nAssessment: Colorectal. <\/span>https:\/\/nccn.org<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n